Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments

Article Ophthalmology

Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration

Ana Bety Enriquez et al.

Summary: In this analysis of brolucizumab intravitreal injection for neovascular age-related macular degeneration, visual acuity remained stable with a reduction in central subfield thickness. Intraocular inflammation events ranged from mild and self-limited to severe occlusive retinal vasculitis in one eye.

JAMA OPHTHALMOLOGY (2021)

添加到收藏夹

Article Ophthalmology

Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study

Manuel Saenz-de-Viteri et al.

Summary: Patients with subretinal fluid (SRF) at the end of the loading phase had better visual outcomes compared to those with intraretinal fluid (IRF). However, the persistence of SRF did not affect visual outcomes across the different treatment regimens. On the other hand, the presence of IRF was associated with poorer visual outcomes, especially in the fixed bimonthly (FBM) group.

ACTA OPHTHALMOLOGICA (2021)

添加到收藏夹

Article Medicine, General & Internal

Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study

Alper Bilgic et al.

Summary: The study aimed to determine the efficacy and safety of intravitreal brolucizumab therapy for neovascular age-related macular degeneration in real-world settings. Results showed good anatomical and functional responses to the treatment, with two significant untoward events noted.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Ophthalmology